| |
| |
|
| Insider
Information: |
Benevich Eric |
| Relationship: |
Chief Commercial Officer |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
40,778 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$5,685,677 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
40,778 |
|
|
| Total
Value |
$5,685,677 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neurocrine Biosciences Inc |
NBIX |
Chief Commercial Officer |
2024-04-15 |
40,778 |
2017-02-06 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-03-14 |
4 |
AS |
$139.38 |
$10,453,418 |
D/D |
(75,000) |
40,778 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-02-28 |
4 |
AS |
$134.69 |
$10,101,608 |
D/D |
(75,000) |
40,616 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-30 |
4 |
AS |
$125.90 |
$6,295,085 |
D/D |
(50,000) |
15,643 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-03-14 |
4 |
OE |
$79.02 |
$6,067,628 |
D/D |
75,000 |
110,299 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-02-28 |
4 |
OE |
$43.24 |
$4,025,043 |
D/D |
75,000 |
62,473 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-08 |
4 |
AS |
$125.33 |
$3,082,319 |
D/D |
(24,593) |
15,643 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-04-15 |
4 |
AS |
$133.36 |
$2,643,020 |
D/D |
(19,818) |
40,778 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-30 |
4 |
OE |
$35.99 |
$2,073,275 |
D/D |
50,000 |
35,706 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2020-11-02 |
4 |
AS |
$96.53 |
$1,987,972 |
D/D |
(20,595) |
15,374 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2023-02-07 |
4 |
AS |
$102.29 |
$1,780,868 |
D/D |
(17,390) |
33,501 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2024-04-15 |
4 |
OE |
$81.05 |
$1,609,431 |
D/D |
19,818 |
53,365 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2018-06-01 |
4 |
AS |
$97.34 |
$1,202,164 |
D/D |
(12,350) |
16,690 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-03 |
4 |
AS |
$125.02 |
$1,121,183 |
D/D |
(8,968) |
15,643 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-08 |
4 |
OE |
$41.78 |
$1,027,496 |
D/D |
24,593 |
40,236 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2020-04-15 |
4 |
AS |
$94.65 |
$817,018 |
D/D |
(8,632) |
11,603 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2020-11-02 |
4 |
OE |
$35.99 |
$741,214 |
D/D |
20,595 |
35,969 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2021-01-25 |
4 |
AS |
$120.03 |
$609,371 |
D/D |
(5,077) |
15,805 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-10-17 |
4 |
AS |
$110.82 |
$549,682 |
D/D |
(4,960) |
15,643 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2019-07-15 |
4 |
AS |
$87.44 |
$510,201 |
D/D |
(5,835) |
14,910 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2021-08-16 |
4 |
AS |
$89.62 |
$504,395 |
D/D |
(5,628) |
15,608 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2021-02-08 |
4 |
AS |
$116.76 |
$498,842 |
D/D |
(4,270) |
21,099 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-11-03 |
4 |
OE |
$41.78 |
$374,683 |
D/D |
8,968 |
24,611 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2022-02-07 |
4 |
AS |
$80.68 |
$332,748 |
D/D |
(4,119) |
19,459 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2020-08-05 |
4 |
AS |
$118.85 |
$268,254 |
D/D |
(2,257) |
15,374 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Commercial Officer |
• – – |
2020-02-07 |
4 |
AS |
$103.32 |
$209,747 |
D/D |
(2,030) |
20,087 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
